TK PHARMA - Your health is our most valuable freight.

Toku Discovered Breakthrough CLAiR Technology to Detect Cardiovascular Disease

Toku has discovered breakthrough CLAiR technology. The CLAiR platform will offer an affordable, non-invasive, and point-of-care solution for assessing the risk of cardiovascular disease (CVD) through routine eye exams using fundus retinal images.

The CLAiR technology has been designed to seamlessly integrate with existing retinal imaging cameras. This AI-powered CLAiR technology can interpret the intricate signals present in retinal images of blood vessels, enabling the identification of elevated cardiovascular risk. 

It empowers healthcare professionals to provide real-time assessments of CVD risk, rivalling the accuracy of traditional cardiovascular risk assessment tools, which typically involve a series of measurements and blood tests, often taking weeks to yield results.

These risks can arise from genetic factors or conditions such as hypertension and high cholesterol. The retina, situated at the back of the eye, is unique in its transparency within the vascular system, allowing for straightforward and non-invasive imaging.

The CLAiR technology available, healthcare professionals across various settings will be equipped with the means to detect elevated cardiovascular risk before clinical disease manifests.

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology.